Mixed joys and sorrows!

CompilationFan Dongdong

AbbVie (AbbVie) antipsychotic drug Vraylar may get a substantial boost due to its potential expansion in the depression market

According to AbbVie’s Phase III trial data released on Friday, Vraylar used as an adjuvant therapy in combination with existing antidepressants was significantly better than the control group, but additional analysis results made this positive result more complicated

Specifically, in the 3111-301-001 study, compared with placebo, the total MADRS score of patients receiving 1.

In response, AbbVie President Mike Severino stated on the company’s third-quarter earnings conference call last Friday that despite the mixed data from the Vraylar depression trial, AbbVie still plans to report to the U.

Part of Severino’s argument is that the drug showed "significant clinically significant benefit trends" at both the 4th and 6th week dose strengths

The drug originally did not belong to AbbVie.

Severinoa pointed out in a conference call in July this year that about half of patients with major depression cannot be treated with first-line monotherapy to fully control their symptoms.

GlobalData analyst Philippa Salter regarded Axsome Therapeutics' AXS-05 as the most promising pipeline drug candidate

AbbVie’s other competitor, Biogen, and its partner Sage Therapeutics have recently jointly announced a regulatory submission plan for the new drug zuranolone for depression.

Reference source: AbbVie's Vraylar turns in mixed results in depression, but pharma decides to file for approval anyway